These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 10932288)

  • 1. Retrospective analysis of the use of cyclosporine in myasthenia gravis.
    Ciafaloni E; Nikhar NK; Massey JM; Sanders DB
    Neurology; 2000 Aug; 55(3):448-50. PubMed ID: 10932288
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclosporine in the treatment of myasthenia gravis.
    Lavrnic D; Vujic A; Rakocevic-Stojanovic V; Stevic Z; Basta I; Pavlovic S; Trikic R; Apostolski S
    Acta Neurol Scand; 2005 Apr; 111(4):247-52. PubMed ID: 15740576
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-year treatment with cyclosporine microemulsion for responder myasthenia gravis patients.
    Nagane Y; Suzuki S; Suzuki N; Utsugisawa K
    Eur Neurol; 2010; 64(3):186-90. PubMed ID: 20720424
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prednisolone-sparing effect of cyclosporin A therapy for very elderly patients with myasthenia gravis.
    Nakamura S; Kaneko S; Shinde A; Morita J; Fujita K; Nakano S; Kusaka H
    Neuromuscul Disord; 2013 Feb; 23(2):176-9. PubMed ID: 23237872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients.
    Bonifati DM; Angelini C
    J Neurol; 1997 Sep; 244(9):542-7. PubMed ID: 9352450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mycophenolate mofetil substitution for cyclosporine-dependent myasthenia gravis and nephrotoxicity.
    Lim AK; Donnan G; Chambers B; Ierino FL
    Intern Med J; 2007 Jan; 37(1):55-9. PubMed ID: 17199845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of myasthenia gravis using cyclosporine in 2 dogs.
    Bexfield NH; Watson PJ; Herrtage ME
    J Vet Intern Med; 2006; 20(6):1487-90. PubMed ID: 17186870
    [No Abstract]   [Full Text] [Related]  

  • 8. [Current concept and perspective of immunotherapy for myasthenia gravis: tacrolimus and cyclosporin].
    Yokoyama K
    Nihon Rinsho; 2008 Jun; 66(6):1158-64. PubMed ID: 18540363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunosuppressive agents for myasthenia gravis.
    Hart IK; Sathasivam S; Sharshar T
    Cochrane Database Syst Rev; 2007 Oct; (4):CD005224. PubMed ID: 17943844
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability.
    Meriggioli MN; Ciafaloni E; Al-Hayk KA; Rowin J; Tucker-Lipscomb B; Massey JM; Sanders DB
    Neurology; 2003 Nov; 61(10):1438-40. PubMed ID: 14638974
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A clinical therapeutic trial of cyclosporine in myasthenia gravis.
    Tindall RS; Phillips JT; Rollins JA; Wells L; Hall K
    Ann N Y Acad Sci; 1993 Jun; 681():539-51. PubMed ID: 8357194
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognosis of Ocular Myasthenia Gravis: Retrospective Multicenter Analysis.
    Nagia L; Lemos J; Abusamra K; Cornblath WT; Eggenberger ER
    Ophthalmology; 2015 Jul; 122(7):1517-21. PubMed ID: 25892018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tacrolimus Improves Symptoms of Children With Myasthenia Gravis Refractory to Prednisone.
    Liu C; Gui M; Cao Y; Lin J; Li Y; Ji S; Bu B
    Pediatr Neurol; 2017 Dec; 77():42-47. PubMed ID: 29074055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ocular myasthenia gravis in an academic neuro-ophthalmology clinic: clinical features and therapeutic response.
    Mittal MK; Barohn RJ; Pasnoor M; McVey A; Herbelin L; Whittaker T; Dimachkie M
    J Clin Neuromuscul Dis; 2011 Sep; 13(1):46-52. PubMed ID: 22361625
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case of severe refractory myasthenia gravis in HUKM.
    Hamizah R; Norlinah MI; Tan HJ; Soehardy Z; Halim AG; Rohana AG; Hamidon BB; Kong NC; Raymond AA
    Med J Malaysia; 2006 Dec; 61(5):633-5. PubMed ID: 17623968
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Myasthenia gravis in the elderly: diagnosis, comorbidity and course: 45 cases].
    Fraisse T; Labauge P; Camu W; Arlaud P; de Wazières B
    Presse Med; 2007 Jan; 36(1 Pt 1):9-14. PubMed ID: 17261443
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocular myasthenia gravis: response to long-term immunosuppressive treatment.
    Sommer N; Sigg B; Melms A; Weller M; Schepelmann K; Herzau V; Dichgans J
    J Neurol Neurosurg Psychiatry; 1997 Feb; 62(2):156-62. PubMed ID: 9048716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tacrolimus monotherapy: a promising option for ocular myasthenia gravis.
    Yagi Y; Sanjo N; Yokota T; Mizusawa H
    Eur Neurol; 2013; 69(6):344-5. PubMed ID: 23549260
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclosporine for myasthenia gravis.
    Elkharrat D; Goulon M; Gajdos P
    N Engl J Med; 1987 Sep; 317(12):770. PubMed ID: 3306381
    [No Abstract]   [Full Text] [Related]  

  • 20. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis.
    Tindall RS; Rollins JA; Phillips JT; Greenlee RG; Wells L; Belendiuk G
    N Engl J Med; 1987 Mar; 316(12):719-24. PubMed ID: 3547126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.